Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in this application:

Listing of Claims:

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)

4. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE III



wherein

R_3 is a group selected from the formulae of Table 1, groups 1 to 40, and R_2 is H or Ac; and R_4 is PhCO or Me_3COCO or $CH_3CH=C(CH_3)CO$.

5. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE IV



wherein

R_3 is a group selected from the formulae of Table 2, groups 41 to 95; R_2 is Ac or H; and R_4, is PhCO or Me_3COCO or $CH_3CH=C(CH_3)CO$.

6. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE V



wherein

R_1 is a group selected from the formulae of Table 1, groups 1 to 40;
R_2 is H or Ac;
R_3 is a group selected from the formulae of Table 2, groups 41 to 95.

7. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE VI



wherein

R_1 is a group selected from the formulae of Table 2, groups 41 to 95;
R_2 is H or Ac;
R_3 is a group selected from the formulae of Table 1, groups 1 to 40.

8. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE VII



wherein

R_1 is a group selected from the formulae of Table 1, groups 1 to 40;
R_2 is H or Ac;
R_3 is a group selected from the formulae of Table 1, groups 1 to 40.

9. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE VIII



wherein

R_1 is a group selected from the formulae of Table 2, groups 41 to 95;
R_2 is H or Ac;
R_3 is a group selected from the formulae of Table 2, groups 41 to 95.

10. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE IX



wherein

R_1 is a group selected from the formulae of Table 1, groups 1 to 40;
R_2 is H or Ac;

R_5 is H or selected from the formulae of Table 3;
R_6 is H, and when R_5 is G_{10} from Table 3, the group R_6 is H or Me.

11. (Currently Amended) [A compound of Claim 1 of the formula:] Anti-neoplastic and/or anti-leukemic effective compound:

TYPE X



wherein

R_1 is a group selected from the formulae of Table 2, groups 55 to 95;
R_2 is H or Ac;
R_5 is H or is selected from the formulae of Table 3;
R_6 is H and when R_5 is G_{10} from Table 3, R_6 is H or Me.

12. (Cancelled)
13. (Cancelled)
14. (Cancelled)

15. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 4 or a pharmaceutical acceptable salt thereof.

16. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 5 or a pharmaceutical acceptable salt thereof.

17. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 6 or a pharmaceutical acceptable salt thereof.

18. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 7 or a pharmaceutical acceptable salt thereof.

19. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 8 or a pharmaceutical acceptable salt thereof.

20. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 9 or a pharmaceutical acceptable salt thereof.

21. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 10 or a pharmaceutical acceptable salt thereof.

22. (Original) A pharmaceutical formulation which comprises as an active ingredient a compound of Claim 11 or a pharmaceutical acceptable salt thereof.

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 4.

27. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 5.

28. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 6.

29. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 7.

30. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 8.

31. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 9.

32. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 10.

33. (Original) A method for treating humans in need thereof comprising administering to said humans an anti-cancer or anti-leukemic effective amount of the compound of Claim 11.

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Currently Amended) A method for the production of a compound of claim 4 comprising reacting paclitaxel, cephalomannine or Taxotere® with halogenated or dihalogenated acyl halogenides selected from the formulae of [t]Table 1, groups 1-40[, of claim 1].

39. (Previously Presented) The method of claim 38 wherein the reaction is conducted in the presence of aminobases under temperatures effective to produce any amount of said compound.

40. (Currently Amended) A method for the production of a compound of claim 5 comprising,

(a) reacting paclitaxel, cephalomannine or Taxotere® with halogenated alkyl or aryl formate selected from the formulae of [t]Table 2, groups 41 to 95[, of claim 1], or

(b) reacting paclitaxel, cephalomannine or Taxotere® with the product of the reaction between halogenated phenols selected from the formulae of [t]Table 2, groups 41 to 95[, of claim 1] and triphosgene.

41. (Previously Presented) The method of claim 4 wherein the reaction of part (b) is carried out with a non-separated and non-purified product obtained from said halogenated phenols and triphosgene under an inert atmosphere at temperatures effective to make any amount of said compound.

42. (Currently Amended) A method for the production of a compound of claim 6 comprising

(a) reacting compounds of type 1

TYPE I



with halogenated alkyl or aryl formate selected from the formulae of [t]Table 2, groups 41 to 95, [of claim 1], or

(b) reacting compounds of said type 1 with products obtained between halogenated phenols selected from the formulae of [t]Table 2, groups 41 to 95, [of claim 1,] and triphosgene, at temperatures effective to make any amount of said compound.

43. (Currently Amended) A method for the production of a compound of claim 7 comprising reacting compounds of type II

TYPE II



with halogenated or dihalogenated acyl halogenides selected from the formulae of [t]Table 1, groups 1 to 40, [of claim 1,] in the presence of aminobases at temperatures effective to make any amount of said compounds.

44. (Currently Amended) A method for the production of a compound of claim 8 comprising reacting a compound of type I

TYPE I



with halogenated or dihalogenated acyl halogenides selected from the formulae of [t]Table 1, groups 1 to 40, [of claim 1] in the presence of aminobases at temperature effective to make any amount of said compound.

45. (Currently Amended) A method for the production of a compound of claim 9 comprising

(a) reacting compounds of type II

TYPE II



with halogenated alkyl or aryl formate selected from the formulae of [t]Table 2, groups 41 to 95, [of claim 1,] or

(b) reacting compounds of said type II with the products of the reaction between halogenated phenols selected from the formulae of [t]Table 2, groups 41 to 95, [of claim 1].

46. (Previously Presented) The method of claim 45 part (b) wherein the reaction is carried out under an inert atmosphere and at temperatures effective to make any amount of said compound.

47. (Currently Amended) A method for the production of a compound of claim 10 comprising

(a) reacting N-substituted acyl halogenides selected from the formulae of [t]Table 1, groups 1 to 40, [of claim 1,] α-amino acids when the group $RCH(NH_2)C00H$ where R is selected from the formulae of [t]Table 3, with



BACCATIN III

or



10-DEACETYL BACCATIN III

in the presence of aminobases at a temperature effective to make any amount of said compound; or

(b) reacting halogenated or dihalogenated acyl halogenides selected from the formulae of [t]Table 1, groups 1-40, [of claim 1] with esterified said α-amino acids selected from the

formulae of [t]Table 3, [claim 1,] or with baccatin III or 10-deacetyl-baccatin III.

48. (Currently Amended) A method for the production of a compound of claim 11 comprising

(a) reacting N-substituted halogenides selected from the formulae of [t]Table 2, groups 41 to 95, [of claim 1]with α-amino acids, (when the group $RCH(NH_2)C00H$, where R is selected from the formulae of Table 3) [claim 1], with,



BACCATIN III



10-DEACETYL BACCATIN III

in the presence of aminobases at temperatures effective to make any amount of said compound, or

(b) reacting halogenated phenols selected from the formulae of [t]Table 2, groups 41-95, [of claim 1] and esterified said α-amino acids selected from the formulae of [t]Table 3, [claim 1,] with baccatin III or 10-deacetyl-baccatin III.